Nanosonics Ltd
ASX:NAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (10.7), the stock would be worth AU$4.47 (33% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8 | AU$3.36 |
0%
|
| 3-Year Average | 10.7 | AU$4.47 |
+33%
|
| 5-Year Average | 12.3 | AU$5.14 |
+53%
|
| Industry Average | 2.4 | AU$0.99 |
-70%
|
| Country Average | 1.7 | AU$0.72 |
-79%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Nanosonics Ltd
ASX:NAN
|
1B AUD | 8 | 49.6 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 13.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 1.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 2.4 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.8B USD | 2.3 | 31.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD | 0.8 | -16 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 2.1 | 31.1 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 5 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 1.9 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | 9.6 | -36.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.7 |
| 70th Percentile | 3.5 |
| Max | 3 073.7 |
Other Multiples
Nanosonics Ltd
Glance View
Nanosonics Ltd. engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company is headquartered in Sydney, New South Wales and currently employs 339 full-time employees. The company went IPO on 2007-05-17. The firm's principal activities include manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories. The firm is focused on research, development and commercialization of infection control and decontamination products and related technologies. Trophon technology includes high-frequency ultrasonic vibrations that generates sonically activated hydrogen peroxide (H2O2) mist that kills bacteria, fungi, and viruses. The firm's products include trophon2, Nanosonics Auditpro, and trophon electron paramagnetic resonance (ERP). trophon2 includes AcuTrace radio frequency identification (RFID) technology, which enables digital record keeping and captures disinfection data. Nanosonics Auditpro provides real-time intelligence on ultrasound probes, operators, and infection control events to manage infection prevention practices across organizations.
